A time-dependent covariate survival analysis looked at changes in rosiglitazone doses over time, and the time to MI, cardiovascular death, a combination of the two outcomes, or heart failure. “If anything, rosiglitazone showed a protective effect rather than a harmful effect” for each outcome, he added.
An intention-to-treat analysis found neither cardiovascular benefit nor harm from taking rosiglitazone. Mr. Moritz has no association with GlaxoSmithKline.